Literature DB >> 26279289

T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.

Hans Jakob Hartling1,2, Carsten Birch1,2, Julie C Gaardbo1,2, Malene Hove1,2, Marius Trøseid3, Mette Rye Clausen4, Jan Gerstoft1, Henrik Ullum2, Susanne Dam Nielsen1.   

Abstract

Direct-acting antiviral has replaced pegylated interferon-α and ribavirin-based treatment in the treatment of chronic hepatitis C virus (HCV) infection. While interferon-α is immune modulating and causes lymphopenia, interferon-free regimens seem to be well-tolerated. This study aimed to compare T-cell homeostasis before, during, and after HCV treatment with or without interferon-α in patients with chronic HCV infection. A total of 20 patients with chronic HCV infection were treated with pegylated interferon-α and ribavirin, and six patients were treated with an interferon-free regimen. All patients were treated for a minimum of 12 weeks. Interferon-α treatment caused an increase in the density of the receptor for IL-7 (IL-7Rα) during treatment, while interferon-free regimens caused a decrease in IL-7Rα density. After a sustained viral response, proportions of IL-7Rα+ T cells and IL-7Rα density decreased compared to prior treatment values. Finally, a proportion of CD8+ effector memory was lower while proportion of apoptotic T cells was higher after sustained virologic response compared to prior treatment. Despite lymphopenia during interferon, alterations in T-cell homeostasis during treatment were relatively similar in patients receiving interferon-based treatment and in patients receiving interferon-free treatment, and alterations during and after treatment seem to illustrate a reduced need for high levels of T cells aimed at controlling infection.
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Direct-acting antivirals; HCV treatment; Interleukin-7 receptor; T cells; interferon-α

Mesh:

Substances:

Year:  2015        PMID: 26279289     DOI: 10.1111/apm.12429

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.428


  2 in total

1.  Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.

Authors:  Wei Teng; Wen-Juei Jeng; Wei-Ting Chen; Chen-Chun Lin; Chun-Yen Lin; Shi-Ming Lin; I-Shyan Sheen
Journal:  Cancer Med       Date:  2022-04-18       Impact factor: 4.711

2.  In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.

Authors:  Valentina Telatin; Francesco Nicoli; Chiara Frasson; Nicola Menegotto; Francesco Barbaro; Eleonora Castelli; Elke Erne; Giorgio Palù; Antonella Caputo
Journal:  Front Cell Infect Microbiol       Date:  2019-06-14       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.